Deflazacort
Generic name
Deflazacort
Brand name
ATC Code
H02AB13
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No pharmacokinetic data in children available (SmPC)
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Inflammatory diseases, endocrinologic diseases, neoplastic diseases |
|---|
|
| Duchenne muscular dystrofia (DMD) |
|---|
|
Renal impaiment in children > 3 months
No information available on dose adjustment in renal impairment.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Growth retardation, cerebral pseudotumor, acute pancreatitis, posterior subcapsular cataract, idiopathic intracranial hypertension. [SmPC Calcort]
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Long-term use in children can cause growth- and developmental delay.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Mineralocorticoids | ||
|---|---|---|
| H02AA02 | ||
| Glucocorticoids | ||
|---|---|---|
| H02AB01 | ||
| H02AB02 | ||
| H02AB09 | ||
| H02AB04 | ||
| H02AB06 | ||
| H02AB07 | ||
| H02AB08 | ||
| H02AB08 | ||
Reference
- Vital Pharma Nordic ApS, SmPC Deflazacort (RVG 124419) 19-01-2024, www.geneesmiddeleninformatiebank.nl
Changes
Therapeutic Drug Monitoring
Overdose
